

## INDEX

---

Note: page numbers in *italics* indicate figures;  
page numbers followed by t indicate tables.

- Acetylcholine, histamine release and, 24, 25
- Acid back-diffusion
- hyperemia and, 18
  - mucoid cap in, 16, 17
  - mucosal defense against, 15
- Acid pump, 23
- Acid pump inhibitors
- action sites of, 102
  - adverse reactions to, 111, 112
  - for bleeding ulcer, 159
  - comparisons between, 112t
  - for duodenal ulcer, 110-111
  - effectiveness of, 9
  - for gastric ulcer, 111
  - for *H. pylori* infection, 127, 131-133
  - for penetrating ulcer, 177
  - pharmacokinetics of, 107, 110
- Acid secretion, 9
- abnormal, 43, 48, 50t
  - bleeding ulcers and, 155
  - excess, 43
  - gastrin level and, 24, 25-26
  - inhibition of. See *Acid pump inhibitors*.
  - meal timing and, 95-96, 97
  - mechanics of, 22-23, 23
  - mucosal vulnerability and, 13
  - parietal cells in, 22, 23, 24, 25
  - stimulation of, 24, 25
- Acidification, duodenal, 50
- Acid-resistant mucosal surface, 13, 14, 15
- Adenocarcinoma, 54, 55-56
- Age/aging
- bleeding ulcer incidence and, 155
  - dyspepsia and, 80
  - gastritis and, 46
  - H. pylori* infection and, 63, 64
- NSAID damage and, 70, 82t
- perforation diagnosis and, 173
- prostaglandins and, 22
- ulcer symptoms and, 80-82, 81t-82t
- Alcohol intake
- healing time and, 98
  - ulcer formation and, 34, 80
- Alkalosis, 182
- Aluminum retention, 114
- Aminophylline, 113
- Amitriptyline, 113
- Ammonia, 41
- Amoxicillin, 126t, 127
- Amoxicillin/lansoprazole/clarithromycin combination, 133
- Amoxicillin/omeprazole combination, 133, 134t, 135
- Amoxicillin/PPI/clarithromycin combination, 136-137, 138t, 140
- Angiographic therapy, 163
- Antibiotics, 9, 126t, 127, 128, 129-131. See also specific drug.
- Antisecretory agents. See also *Acid pump inhibitors*;  
*H<sub>2</sub>-receptor antagonists*.
- for bleeding ulcer, 159
  - for *H. pylori* infection, 131-133
- Antisecretory/antimicrobial combinations, 133, 134t, 135-137, 138t-139t, 140-141
- Antral inflammation, 9. See also *Mucosal* entries.
- Antral ulcer, 162
- Aortic penetration of, 177
- Arachidonic acid metabolism pathway, 18, 20
- Arterial embolization, 163
- Atrophy, mucosal, 46, 65
- Axid (nizatidine), 103, 104t
- Biaxin, 134t
- Bicarbonate
- impaired secretion of, 43
  - motility and, 51
  - in mucosal defense, 14, 15
  - vascular transport of, 18, 19, 21
- Biliary tract obstruction, 172

- Biopsy
  - culture of, 87t, 128
  - urease test of, 87t, 89, 128
- Bismuth
  - action sites of, 102
  - adverse reactions to, 118-119
  - for bleeding ulcer, 164
  - cimetidine vs, 115, 118
  - for *H. pylori* infection, 118, 126t, 127, 129-130
  - pharmacokinetics of, 115, 116-117
  - salicylate moiety of, 119
- Bismuth triple therapy, 138t, 140-141
- Bleeding ulcer
  - in child, 81t
  - clinical presentation of, 156-157
  - corticosteroids and, 156
  - death from, 155
  - H. pylori* infection and, 155-156, 165t
  - incidence of, 155
  - NSAIDs and, 156, 164, 166
  - pathogenesis of, 155-156
  - perforation with, 173
  - pH and, 159
  - prognosis of, 156
  - recurrent, 160-161, 163
    - prevention of, 163
  - spontaneous cessation of, 155
  - treatment of
    - in acute episode, 159
    - algorithm for, 158
    - angiographic, 163
    - cost effectiveness of, 163
    - diet in, 157, 159
    - endoscopic, 158, 159, 160-161, 162
    - initial, 157, 158, 159
    - long-term, 164
    - surgical, 162
- Blood groups, 32
- Bone marrow suppression, 106
- Breath test, urea, 86t, 88, 89, 128
- CagA (cytotoxin-associated antigen), 41
- Campylobacter-like organism (CLO) test, 89, 91
- Cancer. See *Gastric cancer*.
- Carcinoid syndrome, 34
- Catalase, 42t, 43
- Causes of ulcer formation. See *Etiology of ulcer formation*.
- Central nervous system, in gastric acid secretion, 24
- Child
  - bismuth in, 119
  - H. pylori* infection in, 81t
  - ulcer in
    - bleeding, 81t
    - symptoms of, 80, 81t
- Cholecystitis, 172
- Cholecystokinin, 27
- Cigarette smoking
  - healing time and, 96
  - prostaglandins and, 70
  - ulcer formation and, 33, 80
- Cimetidine (Tagamet)
  - adverse effects of, 107
  - bismuth vs, 115, 118
  - dosage of, 103, 104t
  - drug interactions with, 107
  - sucralfate vs., 114
- Ciprofloxacin, 113
- Circulation
  - bicarbonate transport and, 18, 19, 21
  - mucosal, 15, 18, 19
  - prostaglandins and, 21-22
- Cirrhosis, 34
- Clarithromycin, 126t, 127-128
- Clarithromycin/amoxicillin/lansoprazole combination, 133
- Clarithromycin/omeprazole combination, 134t, 135-136
- Clarithromycin/PPI/metronidazole or amoxicillin combinations, 136-137, 138t, 140
- Clinical presentation of ulcer, 79-80
  - in child, 80, 81t
  - in elderly, 81-82, 82t
  - medical history and, 80
  - patient age and, 80-82

- penetrating, 177
- perforated, 171-172
- physical findings in, 82-83
- CLO (campylobacter-like organism) test, 89, 91
- Clostridium difficile* infection, 126t, 130
- Coffee intake
  - healing time and, 34
  - ulcer formation and, 34
- Colloidal bismuth subcitrate. See *Bismuth*.
- Complications of ulcers
  - bleeding as, 155-156
  - in child, 81t
  - in elderly person, 82t
  - gastric outlet obstruction as, 181-183
  - penetration as, 177-178
  - perforation as, 171-175
  - surgical indications in, 9
- Congestive hypoxia, 50
- Contractility
  - cholecystokinin and, 27
  - prostaglandins and, 22
  - secretin and, 27
- Corticosteroids
  - bleeding ulcer and, 156
  - NSAIDs with, 70, 156
  - ulcer formation and, 33
- Cytokines
  - in mucosal immune response, 18, 20
  - in ulcer pathogenesis, 44-45
- Cytotoxin-associated antigen (CagA), 41
  
- Death
  - from bleeding ulcer, 155
  - from perforating ulcer, 174
- Diagnosis of ulcer
  - biopsy in, 87t
  - in child, 81t
  - in elderly, 81, 82t
  - ELISA in, 86t
  - endoscopy in, 89-91, 128
  - histology in, 87t, 128
  - history taking in, 80

- laboratory testing in, 85-90
- pain in, 79-80, 83
- patient age and, 80-82
- PCR in, 87t
- physical findings in, 82
- radiology in, 91
- saliva test in, 86t, 88
- serology in, 85, 86t, 88
- stool culture in, 87t
- urea breath test in, 86t, 88, 89, 128
- Diet
  - gastric cancer and, 58
  - ulcer formation and, 33, 96
  - ulcer management and
    - bleeding, 157, 159
    - duodenal, 96, 98
- Digoxin, 113
- Drug therapy. See also specific drug or drug type.
  - action sites of, 102
  - effectiveness of, 101
- Duodenal acidification, 50
- Duodenal bulb, 13
- Duodenal ulcer
  - antral inflammation and, 9
  - blood groups and, 32
  - endoscopy of, 91
  - etiology of, 9, 48, 49, 80
  - family history of, 80
  - gastric emptying and, 50-51
  - H. pylori* infection and, 51-52, 52
  - healing rate of, 108
  - host factors in, 43
  - location of, 13
  - NSAIDs and, 156
  - pain in, 79-80
  - patient age and, 80
  - penetration of, 177
  - perforated, plugging/suturing of, 9
  - recurrent, 106, 114, 142t-143t, 163
  - treatment of
    - acid pump inhibitors in, 110-111
    - alcohol intake and, 98

- beverage consumption and, 96, 98
- changes in, 9
- cigarette smoking and, 96
- diet in, 96
- H<sub>2</sub>-receptor antagonists in, 103, 104t, 106
- meal timing in, 95-96, 97
- sucralfate in, 113-114
- surgical, 9, 162
- Duodenum
  - epithelial restitution in, 16, 17
  - mucosal circulation in, 18, 19
  - pH of. See *pH*.
- Dyspepsia, 34
  - definition of, 79
  - patient age and, 80
  - ulcer formation and, 34
- ECL (enterochromaffin-like cell)
  - acid pump inhibitors and, 113
  - histamine release by, 24, 25
- Ego strength, 13, 33
- Elderly patient. See also *Age/aging*.
  - perforation diagnosis in, 173
  - ulcer symptoms, 81-82, 82t
- Electrocautery, 162
- ELISA (enzyme-linked immunosorbent assay), 86t, 88
- Endocrine disease, 34
- Endocrine neoplasia, multiple, type 1, 32
- Endoscopy
  - advantages of, 91
  - for bleeding ulcer, 158, 159, 160-161, 162
  - in child, 81t
  - diagnostic, 89-91, 128
  - for gastric outlet obstruction, 182-183
  - indications for, 91
- Endothelial injury, neutrophil/prostaglandin-mediated, 22
- Enteric nervous system, 24
- Enterochromaffin-like cell (ECL)
  - acid pump inhibitors and, 113
  - histamine release by, 24, 25
- Enzyme-linked immunosorbent assay (ELISA), 86t, 88
- Epidemiology of ulcer formation, 63, 64
- Epithelium
  - in *H. pylori* infection, 21, 39
  - in immune response, 18, 20
  - ion transport in, 21
  - mucous cell renewal in, 14, 15
  - restitution of, 15-16, 17
  - T-cell-mediated damage to, 20-21
  - vacuole formation in, 41, 42t
- Erosive gastritis, 46
- Escherichia coli* toxin, 141, 145
- Etiology of ulcer formation
  - alcohol intake in, 34
  - blood groups in, 32
  - chronic disease in, 34
  - cigarette smoking in, 33
  - coffee intake in, 34
  - corticosteroids in, 33
  - dietary, 33
  - duodenal, 9, 48, 49, 80
  - environmental, 32
  - family aggregation in, 31-32, 80, 81t
  - gastric, 48, 49
  - genetic, 31-32, 80, 81t
  - H. pylori* infection in. See *Helicobacter pylori* infection.
  - hypochondriasis and, 13, 33
  - mastocytosis in, 32
  - psychological stress in, 33
  - twin studies of, 32
- Family aggregation, of ulcer incidence, 31-32, 80, 81t
- Famotidine (Pepcid), 103, 104t
- Fecal transmission, of *H. pylori* infection, 65
- Fibrin, 16
- Fluid and electrolyte disturbance, 182
- Fundal-antral junction, 13
- Galactorrhea, 107
- Gastric acid. See *Acid* entries.
- Gastric cancer
  - acid pump inhibitors and, 113
  - bleeding, 162
  - diet and, 58

- H. pylori* infection and, 39, 53, 58
- histological types of, 54, 55-56
- salt intake and, 53
- stages of, 52-53
- ulcer formation and, 48, 49
- ulcer progression to, 91
- undiagnosed, 106
- Gastric emptying
  - duodenal acidification and, 50
  - rate of, 27
  - ulcer formation and, 50-51
- Gastric lavage, 159
- Gastric metaplasia, 51-52, 52
- Gastric outlet obstruction
  - diagnosis of, 181-182
  - symptoms of, 181
  - treatment of, 182-183
- Gastric ulcer
  - antral inflammation and, 9
  - blood groups and, 32
  - causes of, 9
  - etiology of, 48, 49
  - healing rate of, 106, 109
  - locations of, 13
  - malignant, 91, 106
  - motility and, 50
  - NSAIDs and, 156
  - pain in, 79-80
  - recurrent, 106, 114, 144t
  - treatment of, 98
    - acid pump inhibitors in, 111
    - changes in, 9
    - H<sub>2</sub>-receptor antagonists in, 105t, 106
    - sucralfate in, 114
    - surgical, 162
- Gastrin level
  - acid pump inhibitors and, 111, 113
  - acid secretion and, 24, 25-26
  - motility and, 27
  - pH and, 24, 26, 132
  - postprandial, 43

- Gastritis
  - classification of, 46
  - duodenal ulceration and, 51-52, 52
  - H. pylori* infection and, 9, 13, 47, 51-52, 52
  - natural history of, 65
- Gastroduodenal motility. See *Motility*.
- Gastroduodenal mucosa. See *Mucosa*; *Mucosal* entries.
- Gastroenterostomy, 183
- Genetics of ulcer formation, 31-32
- Granulocytic secretion, 22
- Gynecomastia, 107
  
- H. pylori*. See *Helicobacter pylori* entries.
- H<sup>+</sup>, K<sup>+</sup>-ATPase, gastric acid secretion and, 22, 23
- H<sub>2</sub>-receptor antagonists
  - action sites of, 102, 102
  - adverse reactions to, 106-107
  - in bismuth triple or quadruple therapies, 139t, 140
  - for bleeding ulcer, 159, 164
  - in child, 81t
  - comparisons among, 104t
  - development of tolerance to, 105
  - dosage of, 103
  - drug interactions with, 107
  - for duodenal ulcer, 103, 104t, 106
  - effectiveness of, 9
  - for gastric ulcer, 105t, 106
  - healing rate with, 108-109
  - long and short term use of, 103
  - for penetrating ulcer, 177
  - perforation and, 175
  - pharmacokinetics of, 103
  - sucralfate vs., 114
- Heart, ulcer penetration of, 177
- Heart disease, 34
- Heat shock protein, 145
- Heater probe, 162
- Helicobacter felis* infection, 145
- Helicobacter pylori* bacteria
  - classification of, 41
  - electron micrographs of, 40
  - physical characteristics of, 39, 40, 41, 42t

- as slow pathogen, 41
- survival needs of, 39
- Helicobacter pylori* infection
  - adenocarcinoma and, 54, 55-56
  - bacterial classification and, 41
  - bleeding ulcer and, 155-156, 165t
  - cancer from, 39, 53, 58
  - in child, 81t
  - chronic inflammatory response in, 39
  - diagnosis of, 81t
    - endoscopy in, 89, 91, 128
    - laboratory testing in, 85, 86t-87t, 88
    - radiology in, 91
  - epidemiology of, 63, 64
  - gastritis and, 9, 13, 46-47
  - host factors in, 43
  - humoral and cellular recognition of, 21
  - immune response to, 9, 13, 41, 43, 47
  - incidence of, 9-10, 31, 48, 49, 101
  - intestinal metaplasia and, 47
  - MALT lymphoma and, 53-55
  - mucosal defenses and, 13
  - natural history of, 65
  - NSAIDs and, 70-71, 164, 166
  - pathogenesis of, 21, 44-45
  - perforation and, 173
  - pH and, 15, 132
  - prevention of, 141, 145
  - prostaglandins and, 70-71
  - recurrence of, 31, 141, 142t-144t, 145, 164, 165t
  - symptoms of, 47
  - T-cell-mediated damage in, 21
  - transmission of, 65
  - treatment of
    - algorithm for, 128
    - antibiotics in, 9, 126t, 127, 128, 129-131
    - antisecretory, 131-133
    - antisecretory/antimicrobial combinations in, 133, 134t, 135-137, 138t-139t, 140-141
    - bismuth in, 118, 127, 129-130
    - compliance with, 125
    - cost of, 131

- duration of, 125
- future directions in, 141, 145
- general principles in, 125, 127
- metronidazole in, 126t, 127, 130
- omeprazole in, 127
- PPI triple therapies in, 136-137, 138t-139t, 140-141
- ranitidine in, 127
- side effects in, 130
- ulcer formation and, 48, 49, 50t, 50-52, 52, 101
  - duodenal, 51-52, 52
- ulcer relapse in, 141, 142t-144t, 145
- vaccine for, 141, 145
- virulence factors in, 39, 41, 42t
- Hemorrhage. *See Bleeding ulcer.*
- Hemostasis, 16, 17
- Histamine-stimulated acid secretion
  - gastrin and, 24
  - prostaglandins and, 21
- Histology
  - diagnostic, 87t, 89, 128
  - of gastric cancer, 56-57
- History taking, 80
- Hunger pain, 79
- Hyperemia, 18
- Hyperparathyroidism, 34
- Hypochloremic alkalosis, 182
- Hypochondriasis, 13, 33
- Hypokalemic alkalosis, 182
- Hypoxia, 50
  
- Immune response, mucosal. *See Mucosal immune response.*
- Immunoglobulins, in mucosal immune response, 20, 43
- Impotence, 107
- Indigestion. *See Dyspepsia.*
- Inflammation. *See Mucosal entries.*
- Injection therapy, 162
- Interferon, 44-45
- Interleukin, 44-45
- Intestinal metaplasia, 47
- Ion transport, 21

Ketoconazole, 107  
 Kidney disease, 34  
 Kidney penetration, 177  
  
 Laboratory testing  
   accuracy of, 85  
   serology in, 85, 88  
   usefulness of, 85  
 Lamina propria  
   *H. pylori* infection in, 21  
   immune response in, 20  
 Lansoprazole  
   for duodenal ulcer, 110-111, 112t  
   pharmacokinetics of, 107, 110  
   in PPI triple therapy, 136-137  
 Lansoprazole/clarithromycin/amoxicillin combination, 133  
 Laparoscopic plugging/suturing, 9  
 Laparoscopic vagotomy, 9  
 Laser photocoagulation, 162  
 Leukocytosis, 172  
 Liver disease, 34  
 Liver penetration, 177  
 Losec, 134t  
 Lung disease, 34  
  
 Macrolides, 126t, 127  
 Major histocompatibility complex, 44-45  
 MALT (mucosa-associated lymphoid tissue) lymphoma, 53-55  
 Mast cells  
   in mucosal immune response, 20  
   prostaglandins and, 22  
 Mastocytosis, 32  
 Meal timing, 95-96, 97  
 Metabolic alkalosis, 182  
 Metabolic disease, 34  
 Metaplasia, 47, 51-52, 52  
 Metronidazole, for *H. pylori* infection, 126t, 127, 130  
 Metronidazole/PPI/clarithromycin combination, 136-137, 138t, 140  
 Migrating motor complex, 27  
 Milk intake, 34

Monocytes, 20  
 Motility  
   bicarbonate transport and, 51  
   congestive hypoxia and, 50  
   functions of, 26  
   gastric ulcer and, 50  
   hormones and, 27  
   mucosal vulnerability and, 13  
   speed of, 27  
 Mucoid cap  
   in epithelial restitution, 16, 17  
   in hemostasis, 16  
 Mucosa  
   antral, ulceration frequency in, 13  
   atrophy of, 46  
   circulation in, 15, 18, 19  
   NSAID damage to, 69-70  
 Mucosa-associated lymphoid tissue (MALT) lymphoma, 53-55  
 Mucosal defenses  
   acid-resistant surface in, 13, 14, 15  
   cell renewal in, 14, 16  
   circulation in, 15, 18, 19  
   epithelial restitution in, 14, 16, 17  
   factors interfering with, 13  
   *H. pylori* infection and, 9, 13, 41, 43, 47  
   hierarchy of, 14  
   immune response in. See *Mucosal immune response*.  
   mucus-bicarbonate barrier in, 13, 14, 15  
   neural and muscular systems in, 15, 21  
   NSAIDs and, 13, 69-70  
   prostaglandins in, 15, 21-22  
   psychological stress and, 13, 73-74, 74  
 Mucosal immune response  
   adaptive, 20  
   cell-mediated, 20  
   epithelium in, 18  
   to *H. pylori* infection. See *Helicobacter pylori* infection.  
   inflammation in, 18, 20  
   mechanics of, 18, 20  
   in mucosal defense system, 15

- Mucus-bicarbonate barrier, 13, 14, 15
  - immunoglobulin G and, 20
- Multiple endocrine neoplasia type 1, 32
- Multiple organ failure, 107
- Muscular defenses, 15, 21
- Muscularis mucosae
  - break in, 13
  - in immune response, 21
  - prostaglandins and, 21
  
- Nasogastric suction, 173
- Nephritis, 106-107
- Neural defenses, 15, 21
- Neurotoxicity, of bismuth, 118-119
- Neutrophil
  - activation of, 44-45
  - endothelial injury mediated by, prostaglandins and, 22
- Newhauser's syndrome, 32
- Nitroimidazoles, 126t, 129
- Nizatidine (AxiD), 103, 104t
- Noninvasive testing, 81t
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
  - age/aging and, 70, 81-82, 82t
  - corticosteroids with, 70, 156
  - H. pylori* infection and, 70-71
  - healing time and, 98
  - local effects of, 69-70
  - mucosal defenses and, 13
  - oxygen free radicals and, 70
  - perforation and, 175
  - prostaglandins and, 22, 70
  - systemic effects of, 70-71
  - ulcer formation and
    - bleeding, 156, 164, 166
    - duodenal, 48, 49, 80, 101, 156
    - gastric, 48, 49, 156
- Norfloxacin, 113
- NSAIDs. See *Nonsteroidal anti-inflammatory drugs (NSAIDs)*.
  
- Omeprazole
  - for duodenal ulcer, 110-111, 112t
  - gastric cancer and, 113
  - gastrin level and, 111, 113
  - for *H. pylori* infection, 127
  - pharmacokinetics of, 107, 110
  - in PPI triple therapy, 136-137
- Omeprazole/amoxicillin combination, 133, 134t, 135
- Omeprazole/clarithromycin combination, 134t, 135-136
- Oxygen free radicals, 70
  
- Pain
  - in duodenal vs gastric ulcer, 79
  - location of, 83
  - pathophysiology of, 80
- Pancreatic disease, 34
- Pancreatic penetration, 177
- Pancreatitis, 172-173
- Pantoprazole, 136-137
- Parietal cells
  - in gastric acid secretion, 22, 23, 24, 25-26
  - mass of, 43, 48
  - receptor types on, 24, 25
  - somatostatin and, 26
- Pathogenesis of ulcer formation, 9. See also *Etiology of ulcer formation*.
  - ammonia in, 41
  - H. pylori* infection in. See *Helicobacter pylori* infection.
- PCR (polymerase chain reaction), 87t
- Penetration of ulcer, 177, 178
- Pepcid (famotidine), 103, 104t
- Pepto-Bismol. See *Bismuth*.
- Perforation of ulcer
  - bleeding ulcer with, 173
  - clinical presentation of, 171-172
  - death from, 174
  - definition of, 171
  - diagnosis of, 172, 174-175
  - primary location of, 171
  - radiographic appearance of, 174-175
  - recurrent, 175
  - treatment of, 173-175
- Pericardium, ulcer penetration of, 177
- Peripheral sensory system, 24



Peritonitis, 172  
Personality traits, 13, 33  
pH  
  bleeding ulcer clotting and, 159  
  duodenal, 14, 15  
  gastrin level and, 24, 26, 132  
  *H. pylori* infection and, 15, 132  
  mucoid cap and, 17  
  platelet aggregation and, 16  
Phenylketonuria, 32  
Phenytoin, 113  
Phospholipase, 42t  
Photocoagulation, 162  
Platelet aggregation, 16  
Polymerase chain reaction (PCR), 87t  
Polymorphonuclear cells, 20  
Porphyria cutanea tarda, 34  
PPI therapy (proton pump inhibitor therapy)  
  quadruple, 138t-139t, 140-141  
  triple, 136-137, 138t, 140  
Procainamide, cimetidine interaction with, 107  
Prognosis of ulcer disease, in child, 81t  
Progression of ulcer, mucosal circulation and, 18  
Prostaglandins  
  aging and, 22  
  biological actions of, 21  
  *H. pylori* infection and, 70-71  
  in mucosal defense, 15, 21-22  
  neutrophil-mediated endothelial injury and, 22  
  NSAIDs and, 22, 70  
  smoking and, 70  
Protease, in ulcer formation, 42t  
Proton pump inhibitor (PPI) therapy  
  quadruple, 138t-139t, 140-141  
  triple, 136-137, 138t, 140  
Psychological stress  
  mucosal defenses and, 13, 74  
  ulcer formation, 33, 73-74  
Pyloroplasty, 162  
Pylorus motility, 50

Radiology, diagnostic, 91  
Ranitidine (Zantac)  
  adverse effects of, 107  
  development of tolerance to, 105  
  dosage of, 103, 104t  
  for *H. pylori* infection, 127  
Ranitidine/bismuth citrate combination, 133  
Ranitidine/bismuth citrate/clarithromycin combination, 133  
Recurrent ulcers, 9  
  bleeding, 160-161  
  prevention of, 163  
  in child, 81t  
  duodenal, 106, 114, 142t-143t, 163  
  gastric, 106, 114, 144t  
  *H. pylori* infection and, 31, 141, 142t-144t, 145, 164, 165t  
  perforated, 175  
  
Saliva, blood group antigens in, 32  
Saliva test, 86t, 88  
Salt intake, gastric cancer and, 53  
Secretin, 27  
Secretory agents, 159  
Serology testing, 85, 86t, 88  
Smoking  
  healing time and, 96  
  prostaglandins and, 70  
  ulcer formation and, 33, 80  
Smooth muscles, prostaglandins and, 21  
Somatostatin, 26  
Spicy food, 34, 96  
Splenic penetration, 177  
Stomach  
  abnormal motility in, 50  
  epithelial restitution in, 16, 17  
  integrity of, 13  
  prostaglandins and, 22  
  motility and, 26  
  mucosal circulation in, 18, 19  
  ulcer locations in, 13  
Stool culture, 87t  
Stress

mucosal defenses and, 13, 74  
ulcer formation and, 33, 73-74

#### Sucralfate

action sites of, 102  
adverse reactions to, 114  
cimetidine vs, 114  
drug interactions with, 113  
for duodenal ulcer, 113-114  
for gastric ulcer, 114  
H<sub>2</sub>-receptor blockers vs, 114  
pharmacokinetics of, 113

Superoxide dismutase, 43

#### Surgery

for bleeding ulcer, 162  
for gastric outlet obstruction, 183  
indications for, 9  
for penetrating ulcer, 177  
for perforation, 174

Systemic mastocytosis, 32

Tagamet (cimetidine). See *Cimetidine (Tagamet)*.

T-cells, 20

#### Tetracycline

for bleeding ulcer, 164  
for *H. pylori* infection, 126t, 127, 130  
sucralfate interaction with, 113

#### Theophylline

cimetidine interaction with, 107  
sucralfate interaction with, 113

Treatment methods. See specific method or ulcer type.

Tubule-microvilli-tubule cycle, 22-23

Tumor necrosis factor, 44-45

Twin studies, 32

Type A personality, 13, 33

Urea breath test, 86t, 88, 89, 128

#### Urease

in biopsy testing, 87t, 89, 128  
in ulcer formation, 41, 42t

Vaccine against *H. pylori* infection, 141, 145

Vacuolating cytotoxin (VacA), 41, 42t

#### Vagotomy

for bleeding ulcer, 162  
laparoscopic, 9  
van Allen's mastocytosis, 32

Vascular disease, 34

#### Vascular system

bicarbonate transport by, 19  
mucosal, 18  
prostaglandins and, 22

Vasoconstrictors, 159

Vasopressin, 163

Vena caval penetration, 177

Zantac. See *Ranitidine (Zantac)* entries.

Zollinger-Ellison syndrome, 32, 48, 49, 101